Computer Science · Artificial Intelligence
AN ANALYSIS OF GENETIC FACTORS
Total Hip Arthroplasty, H. Westrich, Babette B. Weksler, Charles J. Glueck, Brianne F. Blumenthal, Eduardo, A. Salvati
See on the mapAbstract
Background: The increased thromboembolic risk associated with total hip arthroplasty is multifactorial. We as-sessed whether the prevalence of abnormalities shown by newer genetic screening tests for thrombophilia and hypofibrinolysis was higher in patients in whom pulmonary embolism had developed after total hip arthroplasty than it was in matched control patients. Methods: Fourteen patients with documented pulmonary embolism after total hip arthroplasty and fourteen matched control patients who had undergone total hip arthroplasty without any clinical indication of throm-boembolism were evaluated for risks of thrombophilia and hypofibrinolysis. Functional tests of hemostasis included evaluations of prothrombin time; activated partial thromboplastin time; levels of fibrinogen, serum homocysteine, protein C and S, and antithrombin III; activated protein-C resistance; and dilute Russell viper venom time. Molecular genetic testing was performed for factor-V Leiden, prothrombin promoter G20210A, methylenetetrahydrofolate reductase C677T, plasminogen activator inhibitor-1 4G/4G, and platelet glycopro-tein IIb/IIIa A1/A2 or A2/A2 mutations. Results: The total number of genetic thrombophilic abnormalities identified was higher in the pulmonary embo-lism group (twenty-four abnormalities) than in the control group (fifteen abnormalities). Only patients with pul-monary embolism were found to have heterozygosity or homozygosity for the prothrombin G20210A mutation